Bank of New York Mellon
TVRD

Bank of New York Mellon’s Tvardi Therapeutics TVRD Stock Holding History

Bank of New York Mellon’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,405
Closed -$55.3K – 4462
2026
Q1 		$55.3K Sell
17,405
-741
-4% -$2.9K ﹤0.01% 4140
2025
Q4 		$78K Buy
18,146
+8,480
+88% +$76K ﹤0.01% 4120
2025
Q3 		$377K Buy
+9,666
New +$275K ﹤0.01% 3754
2024
Q2 		– Sell
-3,986
Closed -$131K – 4284
2024
Q1 		$131K Sell
3,986
-481
-11% -$12.5K ﹤0.01% 4005
2023
Q4 		$119K Sell
4,467
-123
-3% -$5.09K ﹤0.01% 4058
2023
Q3 		$278K Sell
4,590
-665
-13% -$62.4K ﹤0.01% 3834
2023
Q2 		$535K Sell
5,255
-5,999
-53% -$826K ﹤0.01% 3561
2023
Q1 		$1.99M Buy
11,254
+14
+0.1% +$4.69K ﹤0.01% 2809
2022
Q4 		$4.35M Sell
11,240
-743
-6% -$282K ﹤0.01% 2417
2022
Q3 		$4.04M Buy
11,983
+936
+8% +$339K ﹤0.01% 2409
2022
Q2 		$3.63M Sell
11,047
-1,152
-9% -$404K ﹤0.01% 2488
2022
Q1 		$5.34M Buy
12,199
+85
+0.7% +$34.9K ﹤0.01% 2389
2021
Q4 		$5.31M Buy
12,114
+612
+5% +$308K ﹤0.01% 2439
2021
Q3 		$6.4M Buy
11,502
+183
+2% +$91.8K ﹤0.01% 2367
2021
Q2 		$5.81M Buy
11,319
+6,607
+140% +$4.19M ﹤0.01% 2411
2021
Q1 		$3.68M Sell
4,712
-239
-5% -$164K ﹤0.01% 2595
2020
Q4 		$2.7M Sell
4,951
-80
-2% -$41.9K ﹤0.01% 2671
2020
Q3 		$2.3M Sell
5,031
-73
-1% -$42.4K ﹤0.01% 2586
2020
Q2 		$3.14M Buy
5,104
+138
+3% +$76.2K ﹤0.01% 2444
2020
Q1 		$2.36M Buy
4,966
+32
+0.6% +$17.4K ﹤0.01% 2472
2019
Q4 		$2.86M Sell
4,934
-566
-10% -$397K ﹤0.01% 2617
2019
Q3 		$3.62M Buy
5,500
+1,560
+40% +$1.3M ﹤0.01% 2440
2019
Q2 		$3.05M Sell
3,940
-52
-1% -$36.5K ﹤0.01% 2575
2019
Q1 		$2.82M Sell
3,992
-54
-1% -$32.3K ﹤0.01% 2606
2018
Q4 		$1.89M Buy
4,046
+95
+2% +$61.3K ﹤0.01% 2750
2018
Q3 		$3.41M Buy
3,951
+382
+11% +$276K ﹤0.01% 2575
2018
Q2 		$2.46M Sell
3,569
-1
-0% -$508 ﹤0.01% 2740
2018
Q1 		$1.59M Buy
3,570
+112
+3% +$54.3K ﹤0.01% 2941
2017
Q4 		$1.52M Buy
3,458
+88
+3% +$40.1K ﹤0.01% 3005
2017
Q3 		$1.66M Sell
3,370
-1,568
-32% -$785K ﹤0.01% 2942
2017
Q2 		$2.73M Buy
4,938
+1,021
+26% +$648K ﹤0.01% 2658
2017
Q1 		$2.59M Sell
3,917
-162
-4% -$86.5K ﹤0.01% 2692
2016
Q4 		$1.36M Buy
4,079
+1,894
+87% +$608K ﹤0.01% 3089
2016
Q3 		$658K Sell
2,185
-296
-12% -$64.1K ﹤0.01% 3399
2016
Q2 		$429K Sell
2,481
-380
-13% -$82.7K ﹤0.01% 3603
2016
Q1 		$640K Buy
2,861
+147
+5% +$43.9K ﹤0.01% 3314
2015
Q4 		$1.65M Buy
2,714
+890
+49% +$489K ﹤0.01% 2834
2015
Q3 		$938K Buy
1,824
+146
+9% +$97.7K ﹤0.01% 3222
2015
Q2 		$734K Buy
1,678
+1,018
+154% +$393K ﹤0.01% 3496
2015
Q1 		$239K Buy
660
+8
+1% +$3.03K ﹤0.01% 3848
2014
Q4 		$234K Sell
652
-182
-22% -$58.6K ﹤0.01% 3852
2014
Q3 		$252K Buy
834
+175
+27% +$71.9K ﹤0.01% 3831
2014
Q2 		$404K Buy
659
+294
+81% +$158K ﹤0.01% 3662
2014
Q1 		$245K Buy
+365
New +$216K ﹤0.01% 3796

Other funds holding TVRD

AFG
American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SC
Savant Capital Rockford, Illinois $34.1B AUM 22.4% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return

Bank of New York Mellon's TVRD Position: Q2 2026 in Review

Bank of New York Mellon sold out of Tvardi Therapeutics (TVRD) in Q2 2026, closing a stake of 17,405 shares — an estimated $55.3K sold.

Bank of New York Mellon first reported a position in TVRD in Q1 2014 and held it in 44 quarters. The position peaked at $6.4M in Q3 2021. 34 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

  • Bank of New York Mellon reported no remaining Tvardi Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Bank of New York Mellon sold 17,405 Tvardi Therapeutics shares in Q2 2026, an estimated $55.3K.
  • Bank of New York Mellon first reported a position in Tvardi Therapeutics in Q1 2014 and held it in 44 quarters.
  • Bank of New York Mellon's Tvardi Therapeutics position peaked at $6.4M in Q3 2021.
  • 34 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.